Skip to content

Pharminent

Primary Menu
  • Home
    • Pro Hub
Light/Dark Button
Hub
  • Home
  • Pipeline
  • Chasing Dupixent, a biotech aims to make better antibody drugs for eczema
  • Pipeline

Chasing Dupixent, a biotech aims to make better antibody drugs for eczema

BioPharma Dive

Infinimmune, a California startup, is developing treatments it claims might last longer and be more effective than existing atopic dermatitis medications.

Immunology & Inflammation

Read full story

pharminent August 11, 2026 (Last updated: August 11, 2026)

BioPharma Dive

Infinimmune, a California startup, is developing treatments it claims might last longer and be more effective than existing atopic dermatitis medications.

Immunology & Inflammation

Read full story

Post navigation

Previous: Epicrispr lands $90M to advance epigenetic editing drug for rare muscle disease
Next: Trump Executive Order Strips Seven Vaccines From Childhood Immunization Recommendations

Related Stories

  • Pipeline

Beyond GLP1s: The race for nextgen obesity drugs starts in the preclinical models

pharminent September 2, 2026
  • Pipeline

Bausch + Lomb advances dry eye disease drug to Phase 3 despite mid-stage fail

pharminent August 25, 2026
  • Pipeline

Epicrispr lands $90M to advance epigenetic editing drug for rare muscle disease

pharminent August 11, 2026
  • Home
  • Contact
© 2026 All rights reserved. | ReviewNews by AF themes.